Organization
Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
1 abstract
Abstract
Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.Org: Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain, Hematology Department, University Hospital Hôtel-Dieu, Nantes, France, National and Kapodistrian University of Athens, Athens, Greece, Ankara University, Ankara, Turkey, CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France,